Darleukin - Philogen

Drug Profile

Darleukin - Philogen

Alternative Names: Anti-EDB-IL2 antibody conjugate; Anti-EDB-interleukin-2 antibody conjugate; Immunocytokine therapy; L19 interleukin-2 fusion-protein; L19-IL-2; L19-IL2 fusion protein

Latest Information Update: 22 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Philogen
  • Developer Bayer Schering Pharma; Maastricht Radiation Oncology; Philogen
  • Class Antineoplastics; Cytokines; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Immunostimulants; Interleukin-2 receptor agonists; Natural killer T cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Diffuse large B cell lymphoma
  • Phase I Solid tumours
  • No development reported Malignant melanoma; Renal cell carcinoma
  • Discontinued Atherosclerosis; Head and neck cancer; Pancreatic cancer

Most Recent Events

  • 22 Oct 2018 Discontinued - Phase-I for Head and neck cancer (Combination therapy) (Intralesional)
  • 22 Oct 2018 Discontinued - Phase-I/II for Pancreatic cancer (Combination therapy, Late-stage disease) in Germany (IV)
  • 22 Oct 2018 Discontinued - Phase-I/II for Pancreatic cancer (Combination therapy, Late-stage disease) in Italy (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top